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S U M M A R Y
The aim of this study is to determine surgical outcomes and factors affecting seizure outcomes in patients
who harbor supratentorial cavernous angiomas presenting with seizures.
Sixty patients were classiﬁed into the intractable epilepsy group (n = 22) and the sporadic seizure
group (n = 38) and then managed differently in accordance with our guidelines. Patients exhibiting
sporadic seizures were treated by lesionectomy, except for patients harboring mesial temporal lesions.
We performed lesionectomy, extended lesionectomy, standard temporal lobectomy and tailored
resection on 33, 9, 9 and 9 patients, respectively.
Finally, 72.7% (16/22) of patients with intractable epilepsy and 89.5% (34/38) of patients with sporadic
seizures achieved Engel Class I outcomes. A long duration of illness was somewhat related to a poor
outcome in patients with intractable epilepsy, yet this was not true of patients with sporadic seizures.
Other factors which included age at onset, size of the lesions and locations were not related to seizure
outcomes. The role of residual hemosiderin is yet to be discovered.
A lesionectomy alone can be considered a reasonable approach for those patientswho exhibit sporadic
seizures and have an extra-temporal or neo-temporal lesion. In patients with intractable epilepsy and/or
mesial temporal lesions, a more invasive approach could achieve the better seizure outcome.
 2008 Published by Elsevier Ltd on behalf of British Epilepsy Association.
Contents lists available at ScienceDirect
Seizure
journa l homepage: www.e lsev ier .com/ locate /yse izIntroduction
Cerebral cavernous angiomas are known to be found in 0.4–
0.5% of the population1,2 and the incidence has increasedwith the
advent of MRI. In one prospective study,3 the gross detection rate
(per 100 000 adults per year) for cavernous angioma was 0.56
compared with 2.27 for all intracranial vascular malformations. It
has been reported that 34–70% of patients harboring supraten-
torial cavernous angioma have a history of seizures,2 and a risk
rate of new-onset seizures at an estimated rate of 2.4%/patient–
year cumulatively over time.4
Asmany as 60% of patients who have symptomatic seizuresmay
beneﬁt from expectant management with antiepileptic drugs.5–7
Nevertheless, surgical treatments tend to be favored because many
of previous studies8–13 about surgical resection reported relatively* Corresponding author at: Department of Neurosurgery, Samsung Medical
Center, Sungkyunkwan University School of Medicine, 50 IL-Won Dong, Kang-Nam
Ku, Seoul 135-710, Republic of Korea. Tel.: +82 2 3410 3493; fax: +82 2 3410 0048.
E-mail address: nsschong@skku.edu (S.-C. Hong).
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doi:10.1016/j.seizure.2008.05.010good seizure outcomes and emphasized the importance of early
surgery.
But these studies had some limitations from an epileptic point
of view. The ﬁrst problem was that the eligible patients included
the subset of patients whose chief complaint and major concern
were not seizures, so that a selection bias could occur. The second
problem was that most studies mainly dealt with the outcome of
lesionectomy alone and a controlled seizure group, so the reports
of the outcome regarding epilepsy surgery and a medically
intractable group were scarce and the size of the population
was very small. The third problem was that the deﬁnitions of
medical intractability and outcome classiﬁcation were different
in each study, so a misclassiﬁcation bias could occur and the
comparison between the studies was not easy.
We present 60 consecutive patients with seizures who were
divided into the intractable epilepsy group and the sporadic
seizure group at ﬁrst and then managed differently in accordance
with our pre-established guidelines. The surgical outcomes, which
are based on Engel classiﬁcation, comparing the two groups
and the surgical methods will be presented. Then, other factors
affecting seizure outcomes will be discussed.Epilepsy Association.
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Patient population
Between 1995 and 2005, 162 patients were admitted and
operated on with a suspicion of harboring cavernous angiomas in
our institute. Among 162 patients, those who had an infratentorial
lesion and whose chief complaint and major concern were not
seizure attacks were excluded, leaving 70 patients. None of them
had a history of a symptomatic intracerebral hemorrhage. After the
operations, four patients were excluded because pathological
examinations revealed two patients with arteriovenousmalforma-
tion, one patient with meningoangiomatosis and one patient with
cysticercosis. After that, six patients were also excluded because of
a short follow-up period; less than 12 months. Ultimately, 60
patients fell into this study population.
We classiﬁed our patients into the intractable epilepsy group
and the sporadic seizure group. The term ‘medical intractability’
has been deﬁned differently from study to study. Although the
deﬁnition of intractability is still being debated, it is generally
believed that seizures are intractable if they persist, despite
appropriate medical management under the guidance of an
experienced neurologist over a 2-year period. Practically, we think
that this is not true of vascular malformations as cavernous
angiomas, because the risks such as overt hemorrhages or
neurologic deterioration due to mass effect always exist. Thus,
we deﬁned medically intractable epilepsy as seizure attacks that
occurred continuously more than once per month despite at least
two antiepileptic drugs with therapeutic range in a total illness
duration of more than 1 year. There were 22 patients who fulﬁlled
these criteria. The remaining 38 patients who did not fulﬁll these
criteria were all classiﬁed into the sporadic seizure group.
Preoperative examinations
Clinical data from the history of patients were collected
retrospectively. Age at initial seizure attack, sex, duration of
illness, antiepileptic drug regimen and responsiveness to anti-
epileptic drugs were examined based on medical records.
Preoperative MRIs were obtained for all patients. The location,
size and number of lesions were examined and any co-existing
lesions were also examined.
The temporal lesions were classiﬁed according to collateral
sulcus into strictly neocortical and mesial temporal lesions, which
include borderline and anterior temporal lesions. Routine scalp
EEGs were performed on 47 patients including all patients with
intractable epilepsy and/or mesial temporal lesion. Ictal video/EEG
monitorings were performed on 19 patients. All but three patients
harboring mesial temporal lesions received functional imaging
studies which included positron emission tomography, ictal single
photon emission tomography and intracarotid amobarbital testing
(Wada test). Pre- and post-operative neuropsychological testings
were performed wherever possible.
In nine patients among the intractable epilepsy group, subdural
electrode plates (PMT Co., MN, U.S.A.) were placed widely over the
lesion of MRI, the ictal onset zone of scalp EEG and eloquent areas.
Three patients had a mesial temporal lesion and depth electrodes
were positioned together in one of them. After inserting the
electrodes, we analyzed the interictal and ictal epileptiform
discharges during the video/electrocorticography (ECoG) monitor-
ing. The ictal onset zones and the highly irritative zones were
localized, and electrical cortical stimulations were performed to
determine the border with eloquent areas. Intra-operative ECoGs
were used in 34 patients and the pre- and post-resection
electrographic spikes were compared. With the aid of intra- andextra-operative mapping procedures, the extent of resection was
determined to be the areas in which the ictal onset zones, the
highly irritative zones and cavernous angiomas were located. The
electrophysiological monitorings and functional MRIs were also
used if necessary.
Surgical procedures
We treated all patients (n = 56) according to our pre-established
treatment strategy except four patients with multiple lesions.
Multiple lesions were actually found in seven patients. However,
three patients among them were not regarded as having multiple
lesions because the lesions were adjacent to each other, so
complete resection of all multiple lesions was possible. The
remaining four patients who had un-operated lesions of other
types were regarded as if they hadmultiple lesions and underwent
a lesionectomy for the largest lesion only. Only one of them
suffered from intractable epilepsy and had a history of receiving
radiosurgery using a linear accelerator.
If the lesionswerenotmultiplenor deeply located, our treatment
strategies were as follows. Patients (n = 35) exhibiting sporadic
seizures were treated by lesionectomy (n = 26), except for patients
harboringmesial temporal lesions. Thesepatients (n = 9)underwent
standard temporal lobectomy (n = 4) or tailored resection (n = 2)
according to the results of Wada test, regardless of medical
intractability. There were three patients who were exceptionally
treated by lesionectomy despite harboring the mesial temporal
lesion. In fact, two of them underwent partial resection of the
anterior temporal lobe including the lesion and were regarded as if
they underwent lesionectomy, for the convenience of statistical
analysis. All patients (n = 21) with intractable epilepsy were treated
by different methods other than lesionectomy. Patients exhibiting
intractable epilepsy with non-mesial temporal lesions were treated
by extended lesionectomy (n = 9). Twelve patients harboringmesial
temporal lesions were treated by standard temporal lobectomy
(n = 5) or tailored resection (n = 7).
A lesionectomy refers to the complete removal of the cavernous
angioma itself and may entail resection of surrounding hemosi-
derin-laden and gliotic tissue, but does not speciﬁcally or
intentionally include the identiﬁcation and resection of the
surrounding epileptogenic cortex.6 Our strategy was targeted to
remove as much surrounding hemosiderin-laden and gliotic tissue
as possible. Complete resection of the lesion itself with visual
inspection was possible in all patients. Extended lesionectomy
refers to lesionectomy plus corticectomy and involves the surgical
removal of the cavernous angioma as well as the identiﬁcation and
resection of the surrounding epileptogenic cortex. Detailed
techniques about standard temporal lobectomy including amyg-
dalohippocampectomy and tailored resection are delineated
elsewhere. All epilepsy surgeries including standard temporal
lobectomies were performed by the same neurosurgeon.
Post-operative examinations
All patients continued to have follow-ups for more than 1 year.
Thereafter, the further follow-up period was different for each
patient according to the resolution of seizures. The outcome in
relation to seizure control was based on the Engel classiﬁcation,
using all 13 subclasses. Every patient was asked to report the
presence of aura or any kind of seizure attack at each follow-up
visit with an interval of approximately 1–2months. Data about the
regimen and dosage of antiepileptic drugs were collected also. In
41 patients who continued to have follow-ups for more than 2
years, yearly changing Engel Classes were documented individu-
ally, and the last available Engel Class was used for statistical
J.Y. Yeon et al. / Seizure 18 (2009) 14–2016analysis. Completeness of resection and the presence of residual
hemosiderin rim were veriﬁed after the operation on the basis of
T2 weighted and gradient-echo MRI in the available 54 patients.
Statistical analysis
All data collected from each patient were organized in a
database. Categorical datawere compared between the two groups
using Fisher’s exact test. Continuous data were compared using
Mann–Whitney rank test, because these data could not be taken to
assume a normal distribution. Relationships between independent
variables and outcomes were assessed using binary logistic
regression for continuous data and cross-tabulation for categorical
data, supposing that Engel Classes were re-grouped into Class I
against Class II, III and IV (also, Class IA against Class IB–IV). All
statistical tests were two tailed and p values of less than 0.05 were
considered as signiﬁcant after Bonferroni’s correction. All statis-
tical calculations were performed using commercially available
software (SPSS version 13; SPSS Inc., Chicago, IL).
Results
Seizure outcomes in relation to medical intractability
Seizure outcomes of the intractable epilepsy group and the
sporadic seizure group are compared in Table 1 and variables are
listed in Table 2. There were 10 patients whose Engel Class changed
at the last follow-up visit. Six patients improved into Class IC from
Class II and threepatients improved intoClass IIC fromClass III. Only
one patient worsened into Class III from Class II. Finally, 72.7% (16/
22) of patients with intractable epilepsy and 89.5% (34/38) of
patients with sporadic seizures can achieve Engel Class I outcome.
Among thesepatients, 54.5% (12/22) ofpatients and84.2% (32/38) of
patients were completely seizure free since surgery (Engel Class IA),
respectively.
There was no signiﬁcant difference in sex, age at onset or length
of follow up between these two groups. Seizure outcomeswere alsoTable 2
Comparisons of variables between the two groups
Variable Intractable epilepsy group
Males/females 12/10
Mean age at onset (years) 25.3  11.9
Mean duration of illness (years) 7.4 (range, 1–26)
Mean length of follow-up (months) 41.4  23.6
Mean size of lesions (cm) 1.8  0.5
Location (mesial temporal/others) 12/10
Operation (lesionectomy/others) 1/21
Outcome (Engel Class I/others) 16/6
Outcome (Engel Class IA/others) 12/10
a Means are expressed asstandard deviation except for duration of illness. The p values
and Bonferroni’s correction. The p values for other variables are derived from Mann–Whit
Table 1
Summary of ﬁnal seizure outcomes in each group
Group Engel Class I (IA) Engel Class II
Intractable epilepsy group 16 (12) 4
Mesial temporal 9 (8) 1
Other locations 6 (4) 3
Multiple 1 (0) 0
Sporadic seizure group 34 (32) 3
Mesial temporal 8 (8) 1
Other locations 23 (21) 2
Multiple 3 (3) 0
Summary 50 (44) 7of no signiﬁcance, although the sporadic seizure group tended to
show somewhat more favorable outcomes. However, if Engel
Classeswere simply stratiﬁed into Engel Class IA against others (IB–
IV), the intractable epilepsy group showed signiﬁcantly poorer
outcomes. Themean duration of illness, size of lesions, location and
surgical method also differed from each other. In the intractable
epilepsy group, the duration of illness was as long as expected, and
the lesions tended to be small and located in the mesial temporal
lobe.
Seizure outcomes in relation to the surgical methods
Seizure outcomes in relation to surgical methods are summar-
ized in Table 3. There was no signiﬁcant difference between
lesionectomy and other methods. We performed a lesionectomy
on 33 patients. Among them, 29 patients (87.9%) achieved an Engel
Class I outcome and antiepileptic drugs could be tapered off in 25
patients. Three patients showed an Engel Class II outcome and one
patient still suffers from continued seizures with no appreciable
change (Class IVB). Further investigations will be conducted to the
patient with a suspicion of concomitant cortical dysplasia.
Complications occurred in six patients, which included hypesthe-
sia, aphasia, upper extremity monoparesis and hemiparesis.
Extended lesionectomy was performed on nine patients. Six
patients (66.7%) achieved an Engel Class I outcome and anti-
epileptic drugs can be successfully withdrawn from four of them.
The outcome of remaining three patients was Engel Class II. In two
of them, the Class II outcomemight have resulted from insufﬁcient
resection of the epileptogenic cortex. The irritative zone conﬁrmed
by intra-operative ECoG could not be properly resected becausewe
had not given informed consents about temporal lobe resection in
one andwe tried to preservemotor cortex in the other patient with
an insular lesion. Complications developed in two patients, which
were shoulder weakness and hemiplegia.
Standard temporal lobectomy including amygdalohippocam-
pectomyor tailored resectionwas performedon18patients. Seizure
outcomes appeared to be Engel Class I in 15 patients (83.3%) and 12Sporadic seizure group p value
25/13 0.421
28.4  12.5 0.208a
3.4 (range, 0.1–34) 0.000a
31.2  21.6 0.073a
2.4  1.0 0.023a
9/29 0.024
32/6 0.000
34/4 0.298
32/6 0.034
for males/females, location, operation and outcome are derived from Fisher’s exact test
ney rank test.
Engel Class III Engel Class IV Summary
1 1 22
1 1
0 0
0 0
0 1 38
0 0
0 1
0 0
1 2 60
Table 3
Seizure outcomes according to the surgical methods
Surgical methods Engel Class I (IA) Engel Class II Engel Class III Engel Class IV Engel Class I/others Engel Class IA/others Summary
Lesionectomy group 29 (26) 3 0 1 29/4 26/7 33
Non-lesionectomy group 21 (18) 4 1 1 21/6 18/9 27
Extended lesionectomy 6 (4) 3 0 0
Standard temporal lobectomy 8 (7) 0 0 1
Tailored resection 7 (7) 1 1 0
Summary 50 (44) 7 1 2 p = 0.322a p = 0.382a 60
a The p values are derived from Fisher’s exact test.
Table 4
The p values of each variable
Variable Intractable epilepsy group Sporadic seizure group Non-lesionectomy group Lesionectomy group
Class I/others Class IA/others Class I/others Class IA/others Class I/others Class IA/others Class I/others Class IA/others
Age at onset 1.000 1.000 1.000 0.478 1.000 0.660 0.536 1.000
Duration of illness 0.238 0.086 0.238 1.000 0.074 0.006 1.000 1.000
Size of lesions 1.000 0.868 1.000 0.516 1.000 1.000 0.600 0.506
Location 1.000 0.422 1.000 1.000 0.652 0.166 0.476 1.000
All p values are derived from binary logistic regression and Bonferroni’s correction. The location is analyzed as a categorical variable.
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outcomesof theother threepatients corresponded toEngel Class IIC,
Class IIIA and Class IVB each. All three patients suffered from
intractable epilepsy, and two of them were preoperatively
diagnosed as having bilateral temporal lobe epilepsy without
laterality. The patient who showed an Engel Class IIIA outcome did
not pass the Wada test, so the hippocampus was partially removed
although intra-operative ECoG showed multiple spikes. After 54
months of follow-up, he still suffers from continued seizures and
was the only man whose outcome deteriorated to a higher Engel
Class compared with the outcome in the ﬁrst post-operative year.
Further resection of his remaining hippocampus is under considera-
tion. Complications include transient sensory aphasia in one patient
and superior temporal quadrant-anopsia in another.
After the operation, a suitable amount of hippocampus for
pathological examination was obtained from 14 patients. Dual
pathology, which means the coexistence of hippocampal sclerosis
with extra-hippocampal lesion, was found in two patients and their
ﬁnal outcomes were Engel Class IA and Class IIIA, respectively.
Further, there were additional two patients who harbored micro-
scopic changes involving conus ammonis layer 2 (Class IA) and
dentate gyrus (Class IA).
Factors affecting seizure outcomes
The aforementioned variables were analyzed separately in each
group to ﬁnd out which one was related to seizure outcome
irrespective of medical intractability or surgical methods. These
variables included age at onset, duration of illness, size of the
lesions and locations. The results are listed in Table 4. Only
duration of illness showed a statistical signiﬁcance and this wasTable 5
Seizure outcomes according to the residual hemosiderin
Residual hemosiderin Engel Class I (IA) Engel Class II Engel Class III
Residual hemosiderin () 26 (24) 2 1
Residual hemosiderin (+) 19 (15) 4 0
Mild 12 (9) 2 0
Moderate 7 (6) 2 0
Summary 45 (39) 6 1
a The p values are derived from Fisher’s exact test.meaningful in the non-lesionectomy group only when Engel
Classeswere simply bisected into Class IA against the other Classes.
The presence and amount of residual hemosiderin were of no
signiﬁcance in a whole population as shown in Table 5. The
location of residual hemosiderin in relation to cortex was also not
related to seizure outcome. However, in the intractable epilepsy
group and non-lesionectomy group, the residual hemosiderinwas
somewhat related to poor outcome (p = 0.033 and p = 0.091,
respectively) only if Engel Classes were bisected into Engel Class
IA against the others (Class IB–IV). When Engel Classes were
bisected into Engel Class I and the others (Class II–IV), we could
not ﬁnd any signiﬁcant relationship. In the sporadic seizure
group and lesionectomy group, residual hemosiderinwas also not
predictive of poorer outcome.
Discussion
Surgical outcomes
A Medline search addressed to studies on cavernous angiomas,
which included surgically treated cases of more than 30 and was
published from 1995 to 2006, was performed. Differences in
inclusion criteria, deﬁnitions of medical intractability, outcome
classiﬁcations and presurgical diagnoses make a comparison of
seizure outcome in the studies reviewed difﬁcult. Even though
these were not controlled studies, many authors reported that
favorable seizure outcomes could be achieved by lesionectomy
alone as shown in Table 6.
Summing up the above studies,8,9,11,13–16 a lesionectomy alone
can be considered a reasonable approach with a chance for a
seizure-free rate up to 70–90%, and this is especially true for thoseEngel Class IV Engel Class I/others Engel Class IA/others Summary
2 26/5 24/7 31
0 19/4 15/8 23
0 14
0 9
2 p = 1.000a p = 0.369a 54
Table 6
Summary of seizure outcomes after lesionectomy
Author Number Patients with
intractable epilepsy
Operation Minimum
follow-up (months)
Outcomes equal to
Engel Class IA or I
Persistent seizures/relapse
(known cause)
Acciarri et al.14 36 8 Lesionectomy 12 20 (55.6%) ?/9 (mostly due to subtotal
removal)
Cohen et al.9 50 16 (cutoff of 6 months) Lesionectomy 12 35 (70%)-no seizure
during the last
12 months
15 (long preop. seizure
duration and many preop.
seizures)
Zevgaridis et al.13 77 ? (rare) Lesionectomy 12 68 (88.3%) 4/? (pure lesionectomy)
Casazza et al.15 47 12/21 patients with
a seizure history >12
months (7 patients
had insufﬁcient data)
Lesionectomy 30 23/26 with sporadic
seizure (88.5%)
13/21 with epilepsy
for >1 year (61.9%)
Four (two subtotal, one
multiple, one hippocampal
sclerosis)/seven (masked
by long post-op.
anticonvulsant intake?)
Cappabianca et al.8 35 ? (16 patients with
preop. seizures >5 and/
or a seizure history
over 12 months)
Lesionectomy 24 29 (82.9%)-no seizure
during the last 12
months
6/0 (All had preop.
seizures >5 and/or a
seizure history >12 months)
Ojemann and Ogilvy11 38 1 Lesionectomy 2 37 (97.4%) 1/0
Ferroli et al.16 163 ? (99 patients with
a seizure history
over 12 months)
Pure
lesionectomy
6 63/64 (98.4%) with
sporadic seizure 65/99
(65.7%) with epilepsy
for >1 year
17/? (three patients
reoperated due to subtotal
removal)
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year. Therefore, a more invasive approach for patients with
sporadic seizures should be reserved for persistent or relapsing
cases. Our own ﬁnding that 87.5% (28/32) of patients with sporadic
seizures who underwent a lesionectomy achieved an Engel Class I
outcome also supports this. However, this result excluded a subset
of patients harboring mesial temporal lesions. Our clinical data
were collected retrospectively, so this could potentially introduce a
selection bias and overestimate the outcomes. In the mean time, it
is worthy to be considered that the lesion can be an incidental
ﬁnding and may not play any role in seizure onset. As we
experienced in one patient who showed an Engel Class IVB
outcome, this may be the situation in up to 6% of cases in patients
with epilepsy.6
Some authors16,17 argued that a favorable outcome could be
achieved after lesionectomy even in patients with intractable
epilepsy. Kraemer et al.17 reported 73.3% (11/15) of patients with
intractable epilepsy had an Engel Class I outcome after lesionect-
omy. As shown in Table 6, Casazza et al.15 and Ferroli et al.16
mentioned the seizure outcomes of patients with epilepsy lasting
for more than 1 year (chronic epilepsy). However, their success
rate of 61.9–65.7% after lesionectomy might be overstated due to
lax criteria for medical intractability. According to the series by
Baumann et al.,18 only 30.4% (7/23) of patients with intractable
epilepsy who were treated by lesionectomy alone (amygdalohip-
pocampectomy was added in patients with mesial temporal
cavernous angioma) remained free from disabling seizures, 3 years
after surgery.
The fundamental question is whether the excision of epilepto-
genic zone results in a better seizure outcome than mere
lesionectomy. This advantage has not been proved until now.
There was no prospective or large-scaled study on this subject, and
direct comparisons within or between studies were not possible
because of obvious bias in selecting patients. Only a few results
were available in the reviewed literature. Cohen et al.9 reported 5
patients treated by extended lesionectomy together with 50
patients treated by lesionectomy alone. All ﬁve patients remained
seizure-free following extended resection despite exhibiting
intractable epilepsy. About mesial temporal lesions, some cases
drawn from series regarding lesional temporal lobe epilepsy
showed somewhat promising results after lobe resection. Stefan
et al.19 compared the seizure outcomes with respect to the surgical
methods after treating 30 patients. They carried out lesionectomy,extended lesionectomy andmodiﬁed lobe resection in 13, 11, and 6
patients, respectively. Overall, the seizure-free (Engel Class I) rate
achieved after each procedure corresponded to 69.2% (9/13), 36.4%
(4/11) and 50% (3/6), each. They concluded that the surgical
method was not related to the seizure outcome.
Our own results also support their conclusion. However, this
probably resulted from obvious selection bias and, in fact, this
might be a counterevidence that a more invasive approach raised
the seizure outcome in patients with intractable epilepsy.
Although this study has some limitations as a retrospective
uncontrolled study, our seizure-free rate of 71.4% (15/21) after
epilepsy surgery or lobe resection was superior to that of above
studies which dealt with the results after lesionectomy alone in
patient with intractable epilepsy. So, it seems that the results
following the more invasive approach may be somewhat superior
to those of lesionectomy alone, because this approach is more
likely to remove not only the regions of seizure onset but also the
areas involved in seizure propagation and secondary epileptogen-
esis.6,20–22
Factors affecting seizure outcomes
The lesions located in the temporal area are worthy of concern.
Although there are some reports8,9,23 that seizure outcome after
surgical resection was not related to the location, many of the
articles10,15,24,25 commented that temporal cavernous angiomas
had a worse prognosis and showed a tendency to be associated
with intractable epilepsy. These differences probably resulted from
differences in constituents harboring mesial temporal lesions
involving the hippocampus. In patientswith peri-limbic or anterior
temporal lesion, dual pathology may co-exist either macroscopi-
cally or microscopically or only functional abnormalities within
hippocampus may exist.22,26
Our result revealed that mesial temporal lesions were
associated with intractable epilepsy and the location was not
related to seizure outcomes as a single factor as shown in Tables 1
and 4. But it does not mean that the mesial temporal lesion can be
overlooked in patients with sporadic seizures, because the
majority of our patients harboring mesial temporal lesions were
not treated by lesionectomy alone irrespective of medical
intractability. It is noteworthy that all six patients with sporadic
seizures were completely seizure-free since resection of their
temporal lobe (Engel Class IA). So, the mesial temporal location of
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decisions for treatment are made even if they exhibit sporadic
seizures and a quite favorable outcome can be anticipated with a
more invasive approach.
At the same time, the duration of seizures should also be
considered together with frequency. This is a necessity for medical
intractability, which is a key factor for approaching patients. Most
studies8–13 about seizure outcome after surgery are in agreement
that a long preoperative duration of illness is associated with a
poor outcome. In other words, early operation, which reduces the
preoperative duration of seizures, is associated with a better
outcome. These ﬁndings are also supported by the series with
arteriovenous malformations25,27 and with lesional mesial tem-
poral lobe epilepsy.28 However, our own ﬁndings show that these
results cannot be applied to all patients. The fact that a long
duration of illness was not related to seizure outcome in patients
with sporadic seizures may suggest that the results of previous
studies were possibly obscured by medical intractability as a
confounding variable.
In the mean time, in patients with intractable epilepsy, a long
duration of illness was somewhat related to poor outcome only
when Engel Classes were simply bisected into Class IA against the
other Classes, although it was not statistically signiﬁcant after
Bonferroni’s correction (p = 0.086). This discrepancy from different
classiﬁcation schemes could be explained by the so-called running
down phenomenon. The hypothetical explanation of the running
down phenomenon is thought to be the ‘de-kindling’—an opposite
process to secondary epileptogenesis, where the induced synaptic
dysfunction gradually declines in the surrounding epileptogenic
cortex after pace-maker resection.29 There were four patients with
intractable epilepsy whose Class was shifted to Class IC from Class
II. Though their duration of illness was somewhat long when
compared with those who had Class IA outcomes, it was relatively
short when compared with those who showed worse outcomes.
The fact that the duration of illness was signiﬁcantly related to
poor outcome in non-lesionectomy group (p = 0.006) implies that
it wasmeaningful not only in patientswith intractable epilepsy but
also in those patients who exhibited sporadic seizures with mesial
temporal lesions. Accordingly, patients with intractable epilepsy
and/or mesial temporal lesions probably beneﬁt from early
operation, yet this may not be true of patients with sporadic
seizures. Also, it can be cautiously assumed that sporadic seizures
may result from the mass effect itself due to repeated micro-
hemorrhages rather than hemosiderin-related cascades or sec-
ondary epileptogenesis. It is possible to say that the frequency can
also be an important factor. Nevertheless, we could not investigate
the frequency in this study, apart from medical intractability,
because of limited data and difﬁculties in standardization and
classiﬁcation. Further investigation would be required on this
subject. If the frequency has a more important impact on seizure
outcome than the duration, the minimum requirement for
intractability can be reduced to several months arbitrarily.
Another constant debate is the beneﬁt after complete resection
of the surrounding hemosiderin-laden and gliotic tissue. Con-
sidering the hemosiderin-related mechanism of epileptogen-
esis,30,31 it is generally agreed that the hemosiderin-stained or
gliotic tissue should be removed in order to achieve complete relief
of seizures. However, this was merely a hope and could not be
proved in the clinical ground. Indeed, most studies8,13,15,16
suggested that this may be unnecessary, although Zevgaridis
et al.,13 in some part, support the beneﬁt of hemosiderin removal.
Recently, Baumann et al.18 analyzed 31 patients with pharma-
cotherapy refractory epilepsy and reported that 58% (7/12) of
patients, in whom hemosiderin had been removed completely,
were classiﬁed into Engel Class I after 1 year, where as 63% (5/8), inwhom hemosiderin was partially or not removed, were classiﬁed
into Engel Class I after 1 year. Three years after operation, the Class
I outcome deteriorated to 42% (5/12) and 14% (1/7), respectively.
So they concluded that complete removal of hemosiderin-stained
tissue may improve the long-term outcome.
In our study, both the presence and the amount of residual
hemosiderin were not predictive of seizure outcome in a whole
population as other articles. The fact that it wasmeaningful only in
patients with intractable epilepsy who had been completely
seizure-free since surgery (Engel Class IA) is suggestive of a
possible relationship with seizure outcome, but it is not true of
patients with sporadic seizure. Aggressive resection of the
hemosiderin-stained tissue during lesionectomy may be unneces-
sary to patients with sporadic seizures. At the same time, three of
four patients with intractable epilepsy whose Class was shifted to
Class IC from Class II had residual hemosiderin, thus it was also
meaningless in patients who collectively achieved Engel Class I
outcomes. Further, there are some evidences besides our own
ﬁndings that patients with multiple lesions can well tolerate
seizures even if other lesions remained untreated. Putting these
together, we think that the residual hemosiderin can be just one
necessity for continuation of seizures and is not a sufﬁcient
condition for continuation of seizures. It can be hypothesized that
other unknown factors or processes including gliosis may play a
more important role in epileptogenesis.
Conclusions
We managed patients with intractable epilepsy and/or mesial
temporal lesion differently from patients with sporadic seizure in
accordance with our pre-established guidelines. The results
comparing the two groups and the surgical methods were
presented. A lesionectomy alone can be considered a reasonable
approach for those patientswho exhibit sporadic seizures and have
an extra-temporal or neo-temporal lesion. In patients with
intractable epilepsy and/or mesial temporal lesions, a more
invasive approach could achieve the better seizure outcome.
Patients with intractable epilepsy and/or mesial temporal lesions
probably beneﬁt from early operation, yet this may not be true of
patients with sporadic seizures. Other factors which included age
at onset, size of the lesions and locations were not related to
seizure outcomes. The role of residual hemosiderin is yet to be
discovered. Further investigation would be required on the
mechanisms of epilepsy and the impact of the preoperative
seizure frequency.
References
1. Rigamonti D, HadleyMN, Drayer BP, Johnson PC, Hoenig-Rigamonti K, Knight JT,
et al. Cerebral cavernous malformations. Incidence and familial occurrence.
New England Journal of Medicine 1988;319:343–7.
2. Robinson JR, Awad IA, Little JR. Natural history of the cavernous angioma.
Journal of Neurosurgery 1991;75:709–14.
3. Al-Shahi R, Bhattacharya JJ, Currie DG, Papanastassiou V, Ritchie V, Roberts RC,
et al. Prospective, population-based detection of intracranial vascular malfor-
mations in adults: the Scottish Intracranial Vascular Malformation Study
(SIVMS). Stroke 2003;34:1163–9.
4. Moriarity JL, Wetzel M, Clatterbuck RE, Javedan S, Sheppard JM, Hoenig-Riga-
monti K, et al. The natural history of cavernous malformations: a prospective
study of 68 patients. Neurosurgery 1999;44:1166–71. [discussion 1172-1163].
5. Churchyard A, Khangure M, Grainger K. Cerebral cavernous angioma: a poten-
tially benign condition? Successful treatment in 16 cases. Journal of Neurology
Neurosurgery and Psychiatry 1992;55:1040–5.
6. Cosgrove GR. Occult vascular malformations and seizures. Neurosurgery Clinics
of North America 1999;10:527–35.
7. Kondziolka D, Lunsford LD, Kestle JR. The natural history of cerebral cavernous
malformations. Journal of Neurosurgery 1995;83:820–4.
8. Cappabianca P, Alﬁeri A, Maiuri F, Mariniello G, Cirillo S, de Divitiis E. Supra-
tentorial cavernous malformations and epilepsy: seizure outcome after lesio-
J.Y. Yeon et al. / Seizure 18 (2009) 14–2020nectomy on a series of 35 patients. Clinical Neurology and Neurosurgery 1997;99:
179–83.
9. Cohen DS, Zubay GP, Goodman RR. Seizure outcome after lesionectomy for
cavernous malformations. Journal of Neurosurgery 1995;83:237–42.
10. Moran NF, Fish DR, Kitchen N, Shorvon S, Kendall BE, Stevens JM. Supraten-
torial cavernous haemangiomas and epilepsy: a review of the literature
and case series. Journal of Neurology Neurosurgery and Psychiatry 1999;66:
561–8.
11. Ojemann RG, Ogilvy CS. Microsurgical treatment of supratentorial cavernous
malformations. Neurosurgery Clinics of North America 1999;10:433–40.
12. Schroeder HW, Gaab MR, Runge U. Supratentorial cavernous angiomas and
epileptic seizures: preoperative course and postoperative outcome. Neurosur-
gery 1997;40:885.
13. Zevgaridis D, van Velthoven V, Ebeling U, Reulen HJ. Seizure control following
surgery in supratentorial cavernous malformations: a retrospective study in 77
patients. Acta Neurochirurgica (Wien) 1996;138:672–7.
14. Acciarri N, Giulioni M, Padovani R, Galassi E, Gaist G. Surgical management of
cerebral cavernous angiomas causing epilepsy. Journal of Neurosurgical Sciences
1995;39:13–20.
15. Casazza M, Broggi G, Franzini A, Avanzini G, Spreaﬁco R, Bracchi M, et al.
Supratentorial cavernous angiomas and epileptic seizures: preoperative course
and postoperative outcome. Neurosurgery 1996;39:26–32.
16. Ferroli P, Casazza M, Marras C, Mendola C, Franzini A, Broggi G. Cerebral
cavernomas and seizures: a retrospective study on 163 patients who under-
went pure lesionectomy. Neurological Sciences 2006;26:390–4.
17. Kraemer DL, Griebel ML, Lee N, Friedman AH, Radtke RA. Surgical outcome in
patients with epilepsy with occult vascular malformations treated with lesio-
nectomy. Epilepsia 1998;39:600–7.
18. Baumann CR, Schuknecht B, Lo Russo G, CossuM, Citterio A, Andermann F, et al.
Seizure outcome after resection of cavernous malformations is better when
surrounding hemosiderin-stained brain also is removed. Epilepsia 2006;47:
563–6.19. Stefan H, Walter J, Kerling F, Blumcke I, Buchfelder M. Supratentorial caver-
noma and epileptic seizures. Are there predictors for postoperative seizure
control? Nervenarzt 2004;75:755–62. [German].
20. Awad IA, Rosenfeld J, Ahl J, Hahn JF, Luders H. Intractable epilepsy and
structural lesions of the brain: mapping, resection strategies, and seizure
outcome. Epilepsia 1991;32:179–86.
21. Morrell F. The role of secondary epileptogenesis in human epilepsy. Archives of
Neurology 1991;48:1221–4.
22. Yeh HS, Privitera MD. Secondary epileptogenesis in cerebral arteriovenous
malformations. Archives of Neurology 1991;48:1122–4.
23. Robinson Jr JR, Awad IA, Magdinec M, Paranandi L. Factors predisposing to
clinical disability in patients with cavernous malformations of the brain.
Neurosurgery 1993;32:730–5.
24. Stefan H, Hammen T. Cavernous haemangiomas, epilepsy and treatment stra-
tegies. Acta Neurologica Scandinavica 2004;110:393–7.
25. Yeh HS, Tew Jr JM, Gartner M. Seizure control after surgery on cerebral
arteriovenous malformations. Journal of Neurosurgery 1993;78:12–8.
26. Cendes F, Cook MJ, Watson C, Andermann F, Fish DR, Shorvon SD, et al.
Frequency and characteristics of dual pathology in patients with lesional
epilepsy. Neurology 1995;45:2058–64.
27. Piepgras DG, Sundt Jr TM, Ragoowansi AT, Stevens L. Seizure outcome in
patients with surgically treated cerebral arteriovenous malformations. Journal
of Neurosurgery 1993;78:5–11.
28. Wieser HG, Ortega M, Friedman A, Yonekawa Y. Long-term seizure outcomes
following amygdalohippocampectomy. Journal of Neurosurgery 2003;98:751–63.
29. Kelemen A, Barsi P, Eross L, Vajda J, Czirjak S, Borbely C, et al. Long-term
outcome after temporal lobe surgery—prediction of late worsening of seizure
control. Seizure 2006;15:49–55.
30. Ueda Y, Willmore LJ, Triggs WJ. Amygdalar injection of FeCl3 causes sponta-
neous recurrent seizures. Experimental Neurology 1998;153:123–7.
31. Willmore LJ, Triggs WJ. Iron-induced lipid peroxidation and brain injury
responses. International Journal of Developmental Neuroscience 1991;9:175–80.
